Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro
Autor(a) principal: | |
---|---|
Data de Publicação: | 2007 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=3527 http://hdl.handle.net/11449/69570 |
Resumo: | Introduction: To evaluate the efficacy, safety, and tolerability of sertraline for the treatment of Brazilian patients with mild to moderate major depression. Patients and methods: Patients were 18 years old or older treated on an out-patient basis. Previous medications were stopped for a 2-week washout period. Afterwards, patients received sertraline, initial dose of 50 mg/day up to the 4 th week. The dose could then be increased up to 200 mg/day according to the efficacy and tolerability. Therapeutic efficacy was evaluated with the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton scale for depression (HAM-D), and Clinical Global Impression (CGI). Results: 51 patients (42 women) were evaluated regarding efficacy and safety. Treatment with sertraline significantly decreased scores of MADRS, HAM-D e ICGfrom 15.7 ± 6.1; 12.2 ± 3.9 e 3.5 ± 0.6 to 6.2 ± 6.5; 5.4 ± 4.7 e 2.3 ± 1.0 (P < 0.0001), respectively. Sertraline was well tolerated. Gastro-intestinal upset (N=14; 24.6%), headache (N=7; 12.3%), sleep alterations (H-7; 12.3%), dizziness (N-4; 7.0%), and anorexia (N=4; 7.0%) were the most common adverse events. Six patients discontinued the treatment due to adverse events. Conclusion: Sertraline is efficient and presents a favorable safety and tolerability profile for the treatment of Brazilian patients with mild to moderate major depression. © Copyright Moreira Jr. Editora. |
id |
UNSP_a2fd7ebc5612d461fd5dad5192f9b5cc |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/69570 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiroSertraline for the treatment of mild to moderate major depression: Brazilian multicenter studyDepressive disorderDrug therapySerotonin uptake inhibitorsSertralinesertralineadultanorexiaClinical Global Impression scalecontrolled studydepressiondisease severitydizzinessdrug efficacydrug safetydrug tolerabilitydrug withdrawalfemalegastrointestinal symptomheadachehumanmajor clinical studymalesleep disorderIntroduction: To evaluate the efficacy, safety, and tolerability of sertraline for the treatment of Brazilian patients with mild to moderate major depression. Patients and methods: Patients were 18 years old or older treated on an out-patient basis. Previous medications were stopped for a 2-week washout period. Afterwards, patients received sertraline, initial dose of 50 mg/day up to the 4 th week. The dose could then be increased up to 200 mg/day according to the efficacy and tolerability. Therapeutic efficacy was evaluated with the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton scale for depression (HAM-D), and Clinical Global Impression (CGI). Results: 51 patients (42 women) were evaluated regarding efficacy and safety. Treatment with sertraline significantly decreased scores of MADRS, HAM-D e ICGfrom 15.7 ± 6.1; 12.2 ± 3.9 e 3.5 ± 0.6 to 6.2 ± 6.5; 5.4 ± 4.7 e 2.3 ± 1.0 (P < 0.0001), respectively. Sertraline was well tolerated. Gastro-intestinal upset (N=14; 24.6%), headache (N=7; 12.3%), sleep alterations (H-7; 12.3%), dizziness (N-4; 7.0%), and anorexia (N=4; 7.0%) were the most common adverse events. Six patients discontinued the treatment due to adverse events. Conclusion: Sertraline is efficient and presents a favorable safety and tolerability profile for the treatment of Brazilian patients with mild to moderate major depression. © Copyright Moreira Jr. Editora.USPFaculdade de Medicina Universidade Federal de Goiás, Goiânia - GOFundação Faculdade Federal de Ciências Médicas de Porto AlegreFundação Faculdade Federal de Ciências Médicas de Porto Alegre, Porto Alegre - RSDisciplina de Medicina InternaDisciplina de Alergia e Imunopatologia Clínica Faculdade de Medicina Estadual de MaríliaEscola Paulista de Medicina UnifespFaculdade de Medicina de Botucatu UnespFaculdade de Medicina Estadual de MaríliaUSP, São PauloDepartamento de Medicina Clínica Universidade Federal de PernambucoUFPERoyal National Hospital for Rheumatic Diseases Saint Thomas'Hospital UKServiço de Reumatologia Hospital Heliópolis, São Paulo - SP, Rua T 38 No 917 - Setor Bueno, Goiânia - GOInstituição Anis Rassi Hospital, E. Av. J. Alves, 453 - esq. c/ r. 9, CEP 74110-020Faculdade de Medicina de Botucatu UnespUniversidade de São Paulo (USP)Universidade Federal de Goiás (UFG)Fundação Faculdade Federal de Ciências Médicas de Porto AlegreDisciplina de Medicina InternaFaculdade de Medicina de Marília (FAMEMA)Universidade Federal de São Paulo (UNIFESP)Universidade Estadual Paulista (Unesp)Universidade Federal de Pernambuco (UFPE)Saint Thomas'Hospital UKHospital HeliópolisInstituição Anis Rassi HospitalNeto, Abrahão AfiuneBarea, Liselotte MenkeCalamita, Zamir [UNESP]Cavalcanti, FernandoPippa, Maria Guadalupe Barbosa2014-05-27T11:22:26Z2014-05-27T11:22:26Z2007-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article132-137http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=3527Revista Brasileira de Medicina, v. 64, n. 3, p. 132-137, 2007.0034-7264http://hdl.handle.net/11449/695702-s2.0-34248547545Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPporRevista Brasileira de Medicina0,101info:eu-repo/semantics/openAccess2021-10-23T10:54:56Zoai:repositorio.unesp.br:11449/69570Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T20:00:18.248700Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro Sertraline for the treatment of mild to moderate major depression: Brazilian multicenter study |
title |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro |
spellingShingle |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro Neto, Abrahão Afiune Depressive disorder Drug therapy Serotonin uptake inhibitors Sertraline sertraline adult anorexia Clinical Global Impression scale controlled study depression disease severity dizziness drug efficacy drug safety drug tolerability drug withdrawal female gastrointestinal symptom headache human major clinical study male sleep disorder |
title_short |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro |
title_full |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro |
title_fullStr |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro |
title_full_unstemmed |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro |
title_sort |
Sertralina no tratamento de pacientes com depressão maior leve e moderada: Estudo multicêntrico brasileiro |
author |
Neto, Abrahão Afiune |
author_facet |
Neto, Abrahão Afiune Barea, Liselotte Menke Calamita, Zamir [UNESP] Cavalcanti, Fernando Pippa, Maria Guadalupe Barbosa |
author_role |
author |
author2 |
Barea, Liselotte Menke Calamita, Zamir [UNESP] Cavalcanti, Fernando Pippa, Maria Guadalupe Barbosa |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Federal de Goiás (UFG) Fundação Faculdade Federal de Ciências Médicas de Porto Alegre Disciplina de Medicina Interna Faculdade de Medicina de Marília (FAMEMA) Universidade Federal de São Paulo (UNIFESP) Universidade Estadual Paulista (Unesp) Universidade Federal de Pernambuco (UFPE) Saint Thomas'Hospital UK Hospital Heliópolis Instituição Anis Rassi Hospital |
dc.contributor.author.fl_str_mv |
Neto, Abrahão Afiune Barea, Liselotte Menke Calamita, Zamir [UNESP] Cavalcanti, Fernando Pippa, Maria Guadalupe Barbosa |
dc.subject.por.fl_str_mv |
Depressive disorder Drug therapy Serotonin uptake inhibitors Sertraline sertraline adult anorexia Clinical Global Impression scale controlled study depression disease severity dizziness drug efficacy drug safety drug tolerability drug withdrawal female gastrointestinal symptom headache human major clinical study male sleep disorder |
topic |
Depressive disorder Drug therapy Serotonin uptake inhibitors Sertraline sertraline adult anorexia Clinical Global Impression scale controlled study depression disease severity dizziness drug efficacy drug safety drug tolerability drug withdrawal female gastrointestinal symptom headache human major clinical study male sleep disorder |
description |
Introduction: To evaluate the efficacy, safety, and tolerability of sertraline for the treatment of Brazilian patients with mild to moderate major depression. Patients and methods: Patients were 18 years old or older treated on an out-patient basis. Previous medications were stopped for a 2-week washout period. Afterwards, patients received sertraline, initial dose of 50 mg/day up to the 4 th week. The dose could then be increased up to 200 mg/day according to the efficacy and tolerability. Therapeutic efficacy was evaluated with the Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton scale for depression (HAM-D), and Clinical Global Impression (CGI). Results: 51 patients (42 women) were evaluated regarding efficacy and safety. Treatment with sertraline significantly decreased scores of MADRS, HAM-D e ICGfrom 15.7 ± 6.1; 12.2 ± 3.9 e 3.5 ± 0.6 to 6.2 ± 6.5; 5.4 ± 4.7 e 2.3 ± 1.0 (P < 0.0001), respectively. Sertraline was well tolerated. Gastro-intestinal upset (N=14; 24.6%), headache (N=7; 12.3%), sleep alterations (H-7; 12.3%), dizziness (N-4; 7.0%), and anorexia (N=4; 7.0%) were the most common adverse events. Six patients discontinued the treatment due to adverse events. Conclusion: Sertraline is efficient and presents a favorable safety and tolerability profile for the treatment of Brazilian patients with mild to moderate major depression. © Copyright Moreira Jr. Editora. |
publishDate |
2007 |
dc.date.none.fl_str_mv |
2007-03-01 2014-05-27T11:22:26Z 2014-05-27T11:22:26Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=3527 Revista Brasileira de Medicina, v. 64, n. 3, p. 132-137, 2007. 0034-7264 http://hdl.handle.net/11449/69570 2-s2.0-34248547545 |
url |
http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=3527 http://hdl.handle.net/11449/69570 |
identifier_str_mv |
Revista Brasileira de Medicina, v. 64, n. 3, p. 132-137, 2007. 0034-7264 2-s2.0-34248547545 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Revista Brasileira de Medicina 0,101 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
132-137 |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808129148596518912 |